<?xml version="1.0" encoding="UTF-8"?>
<ref id="B37">
 <label>37.</label>
 <mixed-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Ramsauer</surname>
    <given-names>K</given-names>
   </name>
   <name>
    <surname>Schwameis</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Firbas</surname>
    <given-names>C</given-names>
   </name>
   <name>
    <surname>Mullner</surname>
    <given-names>M</given-names>
   </name>
   <name>
    <surname>Putnak</surname>
    <given-names>RJ</given-names>
   </name>
   <name>
    <surname>Thomas</surname>
    <given-names>SJ</given-names>
   </name>
   <etal/>
  </person-group>. 
  <article-title>Immunogenicity, safety, and tolerability of a recombinant measles-virus-based Chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial</article-title>. 
  <source>Lancet Infect Dis.</source> (
  <year>2015</year>) 
  <volume>15</volume>:
  <fpage>519</fpage>â€“
  <lpage>27</lpage>. 
  <pub-id pub-id-type="doi">10.1016/S1473-3099(15)70043-5</pub-id>
  <?supplied-pmid 25739878?>
  <pub-id pub-id-type="pmid">25739878</pub-id>
 </mixed-citation>
</ref>
